Could a diabetes drug protect kidneys in obesity? new trial investigates
NCT ID NCT05536804
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This Phase 2 trial is testing whether tirzepatide, a drug already used for diabetes and weight loss, can improve kidney health in 140 people who are overweight or obese and have chronic kidney disease (with or without type 2 diabetes). The study uses advanced MRI scans to measure changes in kidney fat and blood flow over about 56 weeks. Researchers hope to learn if tirzepatide can reduce kidney fat and improve function, offering a new way to manage kidney disease in this population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aarhus Universitetshospital, Skejby
Aarhus, 8200, Denmark
-
American Health Network of Indiana, LLC - Avon
Avon, Indiana, 46123, United States
-
American Health Network of Indiana, LLC - Greenfield
Greenfield, Indiana, 46140, United States
-
American Health Network of Indiana, LLC - Muncie
Muncie, Indiana, 47304, United States
-
Amsterdam UMC, locatie VUmc
Amsterdam, 1081 HV, Netherlands
-
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, 48098, United States
-
Caimed Investigacion En Salud S.A. de C.V.
Mexico City, 06760, Mexico
-
Centre intégré universitaire de santé et de services sociaux de l'Estrie Centre Hospitalier Universitaire -T
Sherbrooke, J1H 5N4, Canada
-
Centro de Investigación y Gastroenterología
Cuauhtémoc, 06700, Mexico
-
Fadia El Boreky Medicine
Waterloo, N2J 1C4, Canada
-
Grupo Medico Camino Sc
Mexico City, 03310, Mexico
-
Health Pharma Professional Research S.A. de C.V:
Mexico City, 03100, Mexico
-
Indiana University Health University Hospital
Indianapolis, Indiana, 46202, United States
-
Instituto Nacional de Cardiologia Ignacio Chavez
México, 14080, Mexico
-
Investigación Nefrológica
Cuernavaca, 62448, Mexico
-
Kidney Associates of Colorado
Denver, Colorado, 80210, United States
-
Klinik Hietzing
Vienna, 1130, Austria
-
Klinik Landstraße
Vienna, 1030, Austria
-
LMC Clinical Research Inc. (Barrie)
Barrie, L4N 7L3, Canada
-
LMC Clinical Research Inc. (Thornhill)
Concord, L4K 4M2, Canada
-
Providence Medical Research Center - Spokane
Spokane, Washington, 99204, United States
-
Toronto General Hospital
Toronto, M5G 2C4, Canada
-
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
-
University of Washington Medical Center - Montlake
Seattle, Washington, 98195, United States
-
Valley Clinical Trials, Inc.
Northridge, California, 91325, United States
-
Zentrum für klinische Studien Dr Hanusch Gmbh
Vienna, 1060, Austria
-
Ziekenhuisgroep Twente, locatie Almelo
Almelo, 7609 PP, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tirzepatide
What this could lead to
If successful, this could show that tirzepatide helps protect kidney function in people with obesity and chronic kidney disease, potentially leading to a new treatment option.
What could go wrong
This is an early Phase 2 study with only 140 participants, so results may not apply to everyone. The main focus is on MRI changes, not long-term kidney outcomes, and tirzepatide may cause side effects like nausea or vomiting.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.